Actusnews Wire - Diffuseur professionnel d'information corporate et réglementée, autorisé par l'AMF et le CSSF.

  Communiqué de la société THERANEXUS du 09/04/2020

  09/04/2020 - 18:30




Lyon, 9 April 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its results for the year ending 31 December 2019 and reviews its recent clinical milestones and outlook.


Franck Mouthon, Chairman, CEO and co-founder of Theranexus, made the following comments: “In 2019 we pursued our programs, with a Phase Ia clinical trial of THN101 for neuropathic pain, a Phase Ib trial of THN201 in Alzheimer's disease-related cognitive disorders and finally, we announced in late March the positive results of our Phase II trial of THN102 in excessive daytime sleepiness (EDS) in Parkinson's disease. In a parallel endeavor, we will continue to identify new drug candidates via our platform and we have also presented various papers on the importance of neuron-glia interactions as therapeutic targets. In late 2019, Theranexus signed an exclusive, global license agreement for the drug candidate BBDF-101[1] with American foundation BBDF. In expanding our portfolio with BBDF-101, destined to enter a pivotal phase leading directly to approval, and the signing of an industrial partnership to continue developing THN102, the next twelve months promise to be full of highly value-creating milestones”.


2019 full-year financial results


Thierry Lambert, Theranexus' Chief Financial Officer added: “Expenditure for the THN102, THN201 and THN101 developments was kept within the budgets set by the company, which reflects our careful use of our cash. Operational cashflow amounted to €5.0 M over the financial year (compared with €5.5 M in 2018). Moreover, immediately after the announcement of a term sheet with BBDF in July, the company raised €2.2 million in a reserved placement, which helped to increase its cash resources. The company is currently implementing different non-dilutive funding sources (Neurolead PSPC /Development Project for Competitiveness with €2.0 M expected in the coming 12 months, accelerated reimbursement of the 2019 Research Tax Credit for a sum of €2.0 M, government-guaranteed bank loans, etc.) to boost its cash in view of developments planned in the medium term, starting with the BBDF-101 development”.


In k€ (French GAAP) 2019 2018
Turnover 0 0
Operating income 617 175
Other purchases and external charges 5,426 4,969
Wages and social security charges 2,353 2,117
Amortization and depreciation of fixed assets 154 55
Other operating expenses 61 24
Operating expenses 7,994 7,166
Net operating income/(expenses) (7,377) (6,990)
Net financial income/(expense) (241) (31)
Income tax (credit) 2,038 1,721
Net income/(expense) (5,580) (5,301)

The 2019 full-year results were approved by the Company's Board of Directors on 9 April 2020 and were the subject of a report by the Company's Statutory Auditors.


In k€ (French GAAP) 31/03/2020* 31/12/2019
Cash available 7,807 9,452

* non-audited


Other purchases and external expenses amounted to €5,426 K in 2019 compared with €4,969 K in 2018. This increase is mainly due to the clinical programs launched in 2018 and finalized in 2019 to treat Parkinson's disease (Phase II), Alzheimer's disease (Phase Ib) and to a lesser extent the clinical program targeting neuropathic pain.


The increase in salaries and benefits, from €2,117 K in 2018 to €2,353 K in 2019, resulted from the recruitment of new employees in the scientific division in connection with the ramp-up of the research and development platform (18-employee workforce as of 31 December 2019 compared with 14 as of 31 December 2018).


Amortization and depreciation of fixed assets are linked to investments in laboratory equipment in connection with the Neurolead research and development platform.


As a result, the operating loss increased slightly from -€6,990 K in 2018 to -€7,377 K in 2019.


The financial result, mainly reflecting interest on loans and repayable advances, amounted to -€241 K in 2019, compared to -€31 K in 2018 (most of the current debt corresponds to a bank loan contracted in the second half of 2018).


Tax income, almost entirely composed of Research Tax Credit, amounts to €2,038 K compared with €1,721 K in 2018. This income has grown in line with research expenditure.


The company's cash amounted to €7,807 K at March 31, 2020, against €9,452 K at 31 December 2019. Cash outflows for the financial year (excluding cash flow from financing activities) remained under control: €5,000 K in 2019 compared with €5,539 K in 2018.


In light of the expenditure expected over the coming twelve months, and the resources already secured to date, the company is in a position to meet its financial obligations in the coming 12 months.




Drug candidate THN102 – Excessive daytime sleepiness (EDS) in Parkinson's disease

On 31 March[2], Theranexus announced the success of its Phase II multicenter trial led in Europe and the United States involving 75 Parkinson's disease patients with EDS.

THN102 met the primary efficacy endpoint as it significantly reduced EDS in Parkinson's patients with excessive daytime sleepiness (EDS of 16.5 on average) scored on the Epworth Sleepiness Scale (ESS)[3]. The ESS score improved by 3.9 points in patients after treatment with THN102-200/2. This improvement is highly significant (p=0.01) compared with that achieved by the placebo. Moreover, the proportion of patients no longer presenting with excessive daytime sleepiness for the duration of the treatment[4] was considerably higher with THN102-200/2 than in the placebo group (p=0.05).

The trial also demonstrated the excellent tolerability of THN102 and the absence of a negative impact on the disease's other symptoms.

It is estimated that roughly 40% of patients suffering from Parkinson's disease, i.e. 2 million people, are affected by the EDS symptom which generally manifests itself during periods of inactivity. There is currently no approved treatment for this indication.

In light of these positive results, the company plans to join forces with an industrial partner to continue developing and marketing THN102.


In addition, in 2019 an in-depth analysis of the results of the Phase II trial for THN102 on narcolepsy patients corroborated an over-representation of poorly responding narcoleptic patients, thus rendering the trial inconclusive.


Drug Candidate THN201 – Cognitive disorders in patients with Alzheimer's disease

THN201 (donepezil/mefloquine combination) is a drug candidate designed to treat cognitive disorders in patients with Alzheimer's disease or other types of dementia. The company conducted a Phase Ib clinical trial on 150 healthy volunteers and announced the results in January 2020. The trial revealed an extension of the pharmacological profile of THN201 compared to donepezil, the standard-of-care treatment for this indication. The good pharmacological profile of THN201 has led Theranexus to seek an industrial partner to continue its development.


Drug Candidate THN101 – Neuropathic pain

The Phase I program for safety, tolerability and pharmacokinetics in patients with neuropathic pain was completed in 2019. The trial established the good tolerability and pharmacokinetic properties of the product. The Phase II program has already been defined. It will include 370 patients suffering from neuropathic pain of diabetic or post-Zosterian origin (following shingles) in 40 to 45 investigation sites in Europe. The primary endpoint of the trial will be based on a regular self-assessment of the patient's pain by patients themselves using a numerical scale. The company will assess the launch of this clinical trial in accordance with upcoming sources of funding, notably from partners.


Drug Candidate BBDF-101 for Batten disease

In late December 2019, Theranexus and the Beyond Batten Disease Foundation (BBDF) announced an exclusive, global license agreement for the drug candidate BBDF-101 in Batten disease, a rare, fatal, genetic pediatric disorder of the nervous system for which there is no treatment. The agreement covers the clinical development of the drug candidate BBFD-101 pending approval and its commercial use. The clinical trial will begin in 2020 and include efficacy measurements comparing the development of various symptoms to natural disease progression documented on the basis of patient cohorts already followed up as well as the safety and pharmacokinetic profile of BBDF-101. To help secure the clinical development program of BBDF-101, Theranexus made a private investment operation raising €2.2 million in July 2019.


Neurolead, a new platform enabling active agent screening of neuron-glia interactions

In early 2019, Theranexus announced that it had secured funding for a new platform called Neurolead developed in partnership with the French Alternative Energies and Atomic Energy Commission (CEA) and the Collège de France. This next-generation drug candidate discovery platform combines the latest innovations in neuroscience and the use of artificial intelligence tools tailored on a project-by-project basis. It aims to extend and systematize the therapeutic concept promoted by Theranexus by increasing its scope of therapeutic applications on neuron-glia interactions. Neurolead will also optimize the medical value potential of drug candidates by integrating the identification and precise qualification of medical needs from design through to development.


BPI France's funding package of over €6 million in support of Neurolead will be split among Theranexus and its academic partners. Two thirds of this amount will go towards financing Theranexus' activities directly (50% in the form of grants and 50% as advances, repayment of which is conditional on the success of the project), with the remaining third financing the activities of the academic partners (French Alternative Energies and Atomic Energy Commission and the Collège de France) taking part in the platform. Theranexus is currently pursuing preclinical selection and characterization activities for upcoming drug candidates expected to further expand the Company's clinical project portfolio. Further to the signing of the consortium agreement, payment of the first part of the funding amounting to €1 M is expected during the second quarter of 2020.

Moreover, in April 2019, Theranexus signed a research collaboration agreement with IRISA[5] using  artificial intelligence technologies to strengthen the therapeutic targeting of neuroglial interactions of its therapeutic platform. The collaboration enhances the selection and qualification capabilities of new active agents targeting neuroglial interactions.


Scientific update


Two scientific papers were published, one focusing on expanding the proprietary library of glial effector cells in the journal ASSAY and Drug Development Technologies in July 2019, and the other on the clinical pharmacological profile of THN102 in the British Journal of Clinical Pharmacology in August 2019.

In June 2019, Theranexus established its Scientific Board composed of 4 leading experts, which will assist and guide the Company in its choices, especially the development of strategies for identifying, selecting and qualifying drug candidates targeting interactions between the brain's two cell populations, neurons and glial cells, for the treatment of central nervous system (CNS) disorders. The Scientific Board is composed of Dr Didier Cussac, Dr Jean-Antoine Girault, Dr Philippe Marin and Dr Paul Moser under the supervision of Dr Mathieu Charvériat, Theranexus Chief Scientific Officer and Werner Rein, Chief Medical Officer.

Finally in 2019, Theranexus presented numerous papers at scientific conferences, notably on the role of astroglial connexins in the efficacy of THN201 in neurocognitive disorders linked to Alzheimer's disease[6] at the AD/PD conference[7] and its new scientific data on neuron-glia interactions at NeuroFrance and Advances in Cell Based Screening in Drug Discovery. Recently the company presented the mechanism of action and impact of THN101 on neuropathic pain at the European Pain Congress (EFIC) which was held in Valencia in September 2019.


Next financial publication:

Thursday July 9, 2020 (before market opening): Cash position as of 30 June 2020


Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: 





















Thierry Lambert

Chief Financial Officer
[email protected]
ACTUS finance & communication
Caroline Lesage

Investor Relations
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
[email protected]
Florence Portejoie

Media Relations Europe
+ 33 (0)6 07 76 82 83
[email protected]



[1] The Beyond Batten Disease Foundation (BBDF) is the world's largest nonprofit organization dedicated to funding research for a treatment and cure for juvenile (CLN3) Batten disease, a severe pediatric neurodegenerative orphan disorder.


[3] Epworth Sleepiness Scale (ESS – the most widely used sleepiness scale, ranging from 0 to 24)

[4] The ESS score must be under 11 ( ESS<11, Johns, 1997)

[5] French Institute for Research in Computer Science and Random Systems

[6] Involvement of astroglial connexins in the efficacy of THN201 in neurocognitive disorders linked to Alzheimer's disease

[7] Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: x5lvYMdmk5iUlWxpZ5iZbmNnl2eTx5TIa5fImGScmMyaaWlgnG2UmcfGZm9jnmds
- Check this key:

  Original Source : THERANEXUS